Annotation Detail

Information
Associated Genes
IFNL3
Associated Variants
IFNL3 MUTATION
IFNL3 MUTATION
Associated Disease
anemia
Source Database
DisGeNET
Description
The primary endpoint was SVR; secondary endpoints examined include (1) patient and graft survival; (2) effect of anti-viral therapy on liver histology (fibrosis and inflammation); (3) incidence of on-treatment development of ACR, CDR, or PCH; (4) association of recipient and donor IL28B genotype with SVR; and (5) incidence of anti-viral therapy-associated adverse events (anemia, leukopenia, thrombocytopenia, depression) and hepatic decompensation.
Pubmed
26034358
Section of the abstract supporting the evidence
METHODS
Number of the section of the abstract supporting the evidence
2
Number of the sentence supporting the evidence
7
Original source reporting the Gene Disease association
BeFree
DisGENET score for the Gene Disease association
0.00298586059288334
Drugs